The key binary catalyst is the hospital study unblinding in January 2027 — a positive result would support a regular sNDA path; a non-pivotal result would shift to an accelerated approval strategy using expanded-access and published-case data. The CNPV request, if granted, could compress FDA review to 1-2 months. Monitor for pre-sNDA meeting outcomes in late January/February 2027. The chronic study's diagnostic bottleneck (no NAT-positive patients yet) limits near-term readthrough from that program.
Price Chart
Executive Summary
60 Degrees Pharmaceuticals filed an 8-K furnishing an updated investor presentation (October 23, 2026) detailing progress on tafenoquine for babesiosis across three clinical settings. Key developments include: 30 subjects randomized in the blinded hospital study (follow-up completes January 2027), 3 confirmed expanded-access cures, a submitted CNPV request for national-priority review, and a planned sNDA in 2027. The filing is a routine investor update with no new financial data or material definitive agreement.
Key Facts
- 30 hospitalized subjects randomized in the severe acute babesiosis study (2:1 tafenoquine+SOC vs placebo+SOC); blinded follow-up completes in early January 2027
- 3 confirmed expanded-access cures (NAT-negative post-treatment); 2 additional outcomes pending disclosure in November 2026
- Statement of Interest (SOI) for a CNPV (national-priority review voucher) submitted to FDA in September 2026
- Pre-sNDA meeting planned for late January 2027 after hospital study unblinds
- Potential sNDA filing in April/May 2027 with priority-review decision possible in Q4 2027 or mid-2027 via CNPV path
- Chronic babesiosis study (B-FREE) screening shows 2/9 genus dPCR positive but 0/9 B. microti NAT positive; no patient yet qualifies for primary per-protocol analysis
- DSMB reviewed blinded hospital program and recommended completing the originally planned study at N=30; no safety signal prevented continued use
- Published-case reanalysis (45 cases) shows each doubling of uninterrupted treatment duration associated with 27% lower retreatment hazard (95% CI 0.58-0.93)
- Tafenoquine+atovaquone combination observed 6/7 (85.7%) 12-week treatment-free responses vs 1.65/7 (23.5%) expected from concurrent atovaquone duration alone (exploratory Cox model p=0.019)
Financial Impact
No financial data reported in the filing. The company has a $3M market cap and disclosed substantial doubt about going-concern basis in forward-looking statements.
Risk Factors
- Hospital study may not show statistically significant treatment effect at unblinding
- Chronic babesiosis study enrollment slow; no patient has yet qualified for primary per-protocol analysis
- Company has substantial doubt about its ability to continue as a going concern
- Tafenoquine is not FDA-approved for babesiosis; regulatory path depends on totality of evidence
- CNPV request may not be granted, delaying potential review timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-111864 |
| Document: ea0309339-8k_60degrees.htm | 0001213900-26-111864 |
| Document: 0001213900-26-111864-index-headers.html | 0001213900-26-111864 |
| Document: 0001213900-26-111864-index.html | 0001213900-26-111864 |
| Document: 0001213900-26-111864.txt | 0001213900-26-111864 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.8759 | awaiting T+5 | — | $0.8700 (−0.67%) |
Oct 6, 2026 20d ago | Press Release | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Oct 6, 2026 20d ago | 8-K | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Aug 26, 2026 8w ago | EFFECT | $1.08 $0.9495 | ▲ +12.08% | ▲ +11.96% | $0.8700 (+19.44%) |
Aug 14, 2026 10w ago | Press Release | $1.20 $1.13 | ▲ +5.44% | ▲ +4.07% | $0.8700 (+27.20%) |
Jul 30, 2026 12w ago | Press Release | $1.25 $1.15 | ▲ +8.00% | ▲ +11.62% | $0.8700 (+30.40%) |
Jul 1, 2026 16w ago | Press Release | $1.75 $1.55 | ▼ −11.43% | ▼ −11.38% | $0.8700 (−50.29%) |
May 26, 2026 21w ago | Press Release | $1.50 $1.46 | ▼ −2.67% | ▼ −3.75% | $0.8700 (−42.00%) |
May 15, 2026 23w ago | Press Release | $1.39 $1.48 | ▼ −6.47% | ▼ −5.51% | $0.8700 (+37.41%) |
Mar 31, 2026 29w ago | Press Release | $1.75 $1.81 | ▲ +3.43% | ▼ −0.52% | $0.8700 (−50.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers